Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SLC 391

Next Previous
Drug Profile

SLC 391

Alternative Names: SLC-0211; SLC-391; XZB-0004

Latest Information Update: 02 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SignalChem Lifesciences
  • Developer Merck & Co; SignalChem Lifesciences
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Axl receptor tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Non-small cell lung cancer
  • No development reported Acute myeloid leukaemia; COVID 2019 infections; Solid tumours

Most Recent Events

  • 18 Dec 2025 SignalChem Lifesciences Corporation terminates a phase-I/II trial in Non-small cell lung cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater, Combination therapy) in Canada and USA (PO) due to lack of efficacy and enrollment challenges (NCT05860296)
  • 06 Dec 2025 Pharmacodynamics data from a preclinical studies in Acute myeloid leukemia presented at the 67th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2025)
  • 28 Feb 2025 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Combination therapy) in Canada (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top